Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.
News & Analysis: Myriad Genetics
MYGN earnings call for the period ending March 31, 2020.
Have these growth stocks bottomed out? That's probably the wrong question to ask.
More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.
MYGN earnings call for the period ending December 31, 2019.
Poor earnings took many stocks lower Tuesday.
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
Hardly anything went right for the genetic testing company in its fiscal 2020 Q1.